A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
| Autor: | Woyach, Jennifer A. *, Awan, Farrukh, Flinn, Ian W., Berdeja, Jesus G., Wiley, Elizabeth, Mansoor, Sharmeen, Huang, Ying, Lozanski, Gerard, Foster, Paul A., Byrd, John C. |
|---|---|
| Zdroj: | In Blood 4 December 2014 124(24):3553-3560 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|